PRESS RELEASES

MEDIA RELEASES

Released in 2022

December 16SQI Diagnostics Inc. Closes Second Tranche of Private Placement
December 2SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation
November 24SQI Diagnostics Inc. Announces Private Placement of $1.0 Million
November 10SQI Diagnostics Secures Up To $2 Million in FedDev Ontario Funding
October 19SQI Diagnostics Extends Maturity Date of Pivot Credit Facility and Announces Deferral of Certain Interest Payments
October 17Health Canada Approval of RALI-Dx
August 31SQI Announces Grant of Stock Options
August 29SQI Diagnostics Reports Third Quarter 2022 Results
June 20SQI Diagnostics extends maturity date of Pivot Credit Facility
June 17SQI Diagnostics Inc. Announces Closing of $4.05 Million Debt Financing
May 26SQI Diagnostics Reports Second Quarter 2022 Results
April 13SQI Diagnostics Extends Maturity Date Of Pivot Credit Facility
March 25SQI Diagnostics Inc. to Participate in the 2022 Virtual Growth Conference
March 3New York State Approves SQI Diagnostics’ EXACT COVID-19 Antibody Assay
February 28SQI Diagnostics Reports First Quarter 2022 Results
February 14SQI Diagnostics Completes Acquisition of Precision Biomonitoring’s Human Diagnostic Testing Business
February 9SQI Diagnostics Provides Update on Previously Announced Asset Purchase Transaction with Precision Biomonitoring Inc.
January 26SQI Diagnostics – 2021 Annual Financial Results
January 24SQI Diagnostics Inc Signs MOU with UK-Based Owlstone Medical
January 13SQI Diagnostics Inc Congratulates its Partner UHN for Winning $24 Million Award from Government of Canada
January 10SQI Enters Definitive Agreement to Acquire Precision Biomonitoring’s Human Diagnostic Testing Business
MEDIA RELEASES

Released in 2021

November 8SQI Diagnostics Inc. Closes Second and Final Tranche of Private Placement
November 1SQI Diagnostics Inc. Closes First Tranche of Private Placement with Insider Participation
September 24SQI Diagnostics Inc. Announces Private Placement with Insider Participation
September 13SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options
August 30SQI Diagnostics Inc. Announces Grant of Stock Options
August 18SQI Diagnostics Reports Third Quarter 2021 Results
July 23FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients
July 15SQI Diagnostics and AZOVA sign distribution agreement to sell SQI’s COVID-19 HOME Antibody Test
June 15SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders
May 27SQI Diagnostics Inc. Announces Grant of Stock Options
May 21SQI Diagnostics Reports Second Quarter 2021 Results and Announces Departure of CEO and Appointment of Interim CEO
April 13SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant
April 1SQI Diagnostics Submits RALI-Dx™ IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
March 8SQI Diagnostics Receives $2.3 Million in Funds from Shareholder Exercise of Securities
March 1SQI Diagnostics Reports First Quarter 2021 Results
February 18SQI Diagnostics Announces New Corporate Website
February 10SQI Diagnostics Announces Proposed Insider Sales and Warrant Exercises to Fund Company
January 27SQI Diagnostics Reports Fourth Quarter and Fiscal 2020 Results
January 25SQI Diagnostics Announces Patient Enrollment Begins for Its COVID-19 HOME Antibody Test Clinical Study